Search 

Meet Axol Bioscience at the UK Pavilion (Hall B, Stand 2348).

We support your pursuit of more effective, safer therapies. Like you, we believe that having more human-relevant disease models will expand scientificknowledge and de-risk drug development. We usehuman iPSCs to achieve this and have been doingso since 2006.We use donated cells from patients and iPSC technology to build physiologically relevant in vitromodels.

We have a special focus on neurodegenerative diseases like Alzheimer’s disease as well ascardiotoxicity to promote drug safety. When working with candidate compounds or novel therapies, our in vitro platforms give you betterearlier-stage modeling and safety testing and later-stage efficacy evaluation and improved patientselection.

With these data comes better insights, helping you de-risk projects, reduce costs, and save timeduring drug development.At Axol Bioscience, we help your science with better models of human disease.

Meet Cancer Research Horizons at the UK Pavilion (Hall B, Stand 2348).

Cancer Research Horizons is the innovation arm of Cancer Research UK – the world's largest charitable funder of cancer research. We bring together world-leading minds, bold ideas and the right partners to bridge the gap between academic research and taking drugs to market. We focus on the tougher, more profound ideas that can lead to true innovation, translating them into effective treatments and diagnostics for cancer patients.

To date, we've played an instrumental role in forming over 60 spin-out companies. We've helped bring 11 cancer drugs to market, borne out of Cancer Research UK's pioneering research. Through these drugs, we have enabled in excess of 6 million courses of treatment for cancer patients across the world. With access to Cancer Research UK's network of 4000 exceptional researchers and clinicians, and £300+ million of annual research spend, we're a powerful partner in the fight to conquer cancer.

Meet Epitopia at the UK Pavilion (Hall B, Stand 2348).

Epitopea is a recently established cancer immunotherapeutics company based in Cambridge (UK) and Montreal(Canada). We are translating the work of our scientific founders, Claude Perreault and Pierre Thibault who asked: what unique features of cancer cells are visible to T cells and can be targeted for immunotherapies? Using immunopetidomics, our founders discovered mutation-containing tumour-specific antigens (TSAs) detectable by mass spec are rare and dramatically outnumbered by aberrantly expressed or cryptic TSAs arising from a variety of dysregulations common in cancer, such as alternative splicing, dysregulated epigenetic control and loss of translational fidelity. These TSAs have a far greater chance of being shared between patients than mutation-containing TSAs; furthermore, emerging results indicate a great many of them are immunogenic and that they are likely to be amongst the targets exploited by immune checkpoint blockade. Epitopea intends to define and develop a pipeline of therapeutic vaccines for durable cancer control.

Meet Phaim at the UK Pavilion (Hall B, Stand 2348).

Phaim is developing novel therapies for the treatment and early detection of autoimmune disease with a lead product in Type1 Diabetes. Phaim’s platform approach to autoimmunity will recapitulate the normal regulatory immune response, preventing the onset of T1DM in prediabetics, and facilitating the use of cellular therapies in the treatment of established T1DM patients. The platform has means of identifying targets in other autoimmune diseases, such as psoriasis and we would look to produce other therapies after our successful T1DM trial. Furthermore, with our proprietary diagnostic kit, we will be able to predict who is likely to get T1DM and in what time frame. By doing so, we could potentially treat before the disease develops and look to ameliorate the need for insulin. In short, Phaim canpredict, prevent and potentially treattype 1 diabetes and other autoimmune conditions. Phaim's T1D therapy alone has a potential of world-wide market capture.